BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
First published online March 16, 2009
British Journal of Radiology (2009) 82, 748-755
© 2009 British Institute of Radiology
doi: 10.1259/bjr/57217783
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by KARAMBATSAKIDOU, A
Right arrow Articles by FRANSSON, A
PubMed
Right arrow PubMed Citation
Right arrow Articles by KARAMBATSAKIDOU, A
Right arrow Articles by FRANSSON, A

Effective dose conversion factors in paediatric interventional cardiology

A KARAMBATSAKIDOU, MSc 1 B SAHLGREN, MD, PhD 2 B HANSSON, MSc 3 M LIDEGRAN, MD, PhD 4 and A FRANSSON, PhD 1

Departments of 1 Medical Physics and, 2 Paediatric Cardiology, Karolinska University Hospital, S-171 76 Stockholm, 3 Department of Hospital Physics, Danderyd Hospital, S-182 88 Stockholm, and 4 Department of Paediatric Radiology, Karolinska University Hospital, S-171 76 Stockholm, Sweden

Correspondence: A Karambatsakidou, Department of Medical Physics, Karolinska University Hospital, S-171 76 Stockholm, Sweden. E-mail: angeliki.karambatsakidou{at}karolinska.se

Conversion factors for effective dose (CFE  =  effective dose/dose–area product (mSv (Gy cm2)–1) in paediatric interventional cardiology were estimated retrospectively for 249 patients using the dose–area product (DAP), irradiation geometry, exposure parameters and tissue-weighting factors (TWFs) from the International Commission on Radiological Protection (ICRP) 60. Two methods for estimating the conversion factors, which differed in the description of the irradiation geometry, were evaluated. The effective doses obtained with the two methods were almost identical. The results showed that irradiation geometry had no significant impact on the CFE, and a single factor was defined for both diagnostic and interventional examinations. In addition, the effect of the new tissue-weighting factor for breast tissue (TWFb) given in ICRP 103 on the effective dose was assessed. The CFE was 3.7±0.2 mSv (Gy cm2)–1 (neonate), 1.9±0.2 mSv (Gy cm2)–1 (1 year), 1.0±0.1 mSv (Gy cm2)–1 (5 years), 0.6±0.1 mSv (Gy cm2)–1 (10 years) and 0.4±0.1 mSv (Gy cm2)–1 (15 years). Applying these CFs to the individual DAP values of each patient yielded mean effective doses of 13.0 mSv (neonate), 8.6 mSv (1 year), 6.4 mSv (5 years), 8.6 mSv (10 years) and 12.7 mSv (15 years). The maximum estimated skin dose (15 patients) did not exceed 60 mGy. With the new ICRP value for TWFb, increases in the CFs in the order of 10–30%, and in the effective dose of 10–20%, were indicated. The results indicated that the effective dose in paediatric interventional cardiology is of much greater concern than the skin dose. Furthermore, age-dependent CFE values are required so as not to underestimate the doses to very young patients.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 2009 by the British Institute of Radiology.